IMP-IT Subgroup analysis on revascularization extent (R-IMP IT) now published in JACC: Cardiovascular Interventions

The IMP-IT study is a national multicenter retrospective observational registry and 406 consecutive patients, treated with  Impella were  included. Now 297 patients from this registry were re-evaluated regarding the extend of revascularization (R-IMP IT).

JACC: Cardiovascular Interventions: Volume 14, Issue 6, 22 March 2021, Pages 717-719 

https://authors.elsevier.com/a/1ckrP6uPJvj17r

Following the presentation from Francesco Burzotta, MD at TCT Connect 2020 (https://www.heartrecovery.com/education/education-library/clinical-relevance-of-revascularization-extent-in-protected-pci-insight-from-italian-studies) the R-IMP IT data is now published in JACC: Cardiovascular Interventions.

The aim of the study was to assess the association between the extent of coronary revascularization and survival in high risk and cardiogenic shock patients at 1-year follow up. 

• More extensive revascularization achieved during Impella Protected PCI (revascularization index (RI) ≥0.67) is associated with significant reduction in the primary endpoint (all cause death, nonfatal MI, and nonfatal stroke at 1-year follow-up) for the entire study population (high-risk PCI and cardiogenic shock patients)
• Significant reduction in the secondary endpoint of all cause death in the more extensive revascularization group for the entire study population
• Better clinical outcomes in both cardiogenic shock and high-risk PCI subgroups with more complete revascularization
• Operators performing Impella-protected PCI may aim to improve late clinical outcomes by achieving more extensive revascularization
• Because better outcomes were associated with an RI ≥0.67, operators can use their clinical judgment in determining which lesions to treat since not all lesions need to be treated to achieve the clinical advantages

More available resources:

• Clinical Relevance of Revascularization Extent in Protected PCI: Insight From Italian Studies 
• Videointerview with Dr. Cristina Aurigemma (Policlinico Gemelli, Rom)